Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas.

Cancers (Basel) · 2022 · PMC9264992 · PMID 35804808

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

From this model we observed that the treatment with NEO-201 or NEO-201 in combination with the PBMCs, showed a trend towards tumor control.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.